Skip to content
2000
Volume 13, Issue 21
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

In most countries the prevalence of obesity now exceeds 15%, the figure used by the World Health Organization to define the critical threshold for intervention in nutritional epidemics. Here we describe Homo obesus (man the obese) as a recent phenotypic expression of Homo sapiens. Specifically, we classified Homo obesus as a species deficient of metabotrophic factors (metabotrophins), including endogenous proteins, which play essential role in the maintenance of glucose, lipid, energy and vascular homeostasis, and also improve metabolism-related processes such as inflammation and wound healing. Here we propose that pharmaceuticals, nutraceuticals and xenohormetics targeting transcriptional, secretory and/or signaling pathways of metabotrophins, particularly adiponectin, nerve growth factor, brain-derived neurotrophic factor, interleukin-10, and sirtuins, might be new tools for therapy of Homo obesus. Brief comment is also given to (i) exogenous metabotrophic agents represented by various classes of drugs, and (ii) adiponutrigenomics of lifspan.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/138161207781039616
2007-07-01
2025-04-22
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/138161207781039616
Loading

  • Article Type:
    Research Article
Keyword(s): metabotrophin-targeted pharmacology; Metabotrophins
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test